Form 4: Ligand Pharmaceuticals Director Receives Equity Compensation Awards

Ligand Pharmaceuticals Inc. Director John W. Kozarich was granted 1,209 restricted stock units and 5,783 non-qualified stock options on June 6, 2025, as part of his compensation.

Summary

• John W. Kozarich, a Director of Ligand Pharmaceuticals Inc. (LGND), reported changes in his beneficial ownership of company securities.
• On June 6, 2025, Mr. Kozarich acquired 1,209 shares of Common Stock in the form of Restricted Stock Units (RSUs). These RSUs were granted by the Board of Directors at their annual meeting.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock and vests fully on the earlier of the date of the next annual meeting of stockholders following the grant date or the first anniversary of the grant date.
• Additionally, on June 6, 2025, Mr. Kozarich acquired 5,783 Non-Qualified Stock Options with an exercise price of $105.99 per share. These options were also granted by the Board of Directors at their annual meeting.
• The stock options fully vest on the earlier of the date of the next annual meeting of stockholders following the grant date or the first anniversary of the grant date, and they expire on June 6, 2035.
• Following these transactions, Mr. Kozarich beneficially owns 47,390 shares of Common Stock directly and 5,783 Non-Qualified Stock Options directly.

Sentiment

Score: 7

Explanation: The document reports routine equity compensation for a director, which is a positive for aligning interests but not a significant market-moving event. It reflects standard corporate governance practices.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for retaining and motivating key personnel, including directors.

Future Outlook

The granted Restricted Stock Units and Non-Qualified Stock Options are subject to a vesting schedule, fully vesting on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, indicating future potential share acquisition and option exercise for the director.

Management Comments

• The equity awards were acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025.

Industry Context

The granting of equity awards, such as restricted stock units and stock options, to directors is a common and widely accepted practice across various industries, including pharmaceuticals, to align the interests of board members with those of shareholders and to provide performance incentives.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and non-qualified stock options with vesting periods, is consistent with typical compensation packages for non-employee directors in publicly traded companies across the pharmaceutical and biotechnology sectors.
• The vesting schedule, tied to either the next annual meeting or the first anniversary of the grant, is a standard mechanism to ensure continued service and alignment with long-term company performance, comparable to practices at companies like Amgen Inc. or Gilead Sciences, Inc. for their board members.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's performance, potentially leading to more focused decision-making aimed at increasing shareholder value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The Restricted Stock Units and Non-Qualified Stock Options will vest on the earlier of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership